Neuronale Korrelate der prosozialen Emotionsverarbeitung und Schlafphysiologie nach serotonerger Stimulation mit N,N-Dimethyltryptamin (DMT) und Harmin in gesunden Versuchspersonen

Drug: DMT;Drug: Harmine;Drug: Placebo (Harmine);Drug: Placebo (DMT)

Inclusion Criteria:

- Willing and capable to give informed consent for the participation in the study after
it has been thoroughly explained

- Little or no previous experiences with psychedelic substances

- Body mass index (BMI) between 18.5 and 25

- Willing to refrain from drinking caffeine 3 days and alcohol the day before testing
session, from drinking alcohol and caffeinated drinks at the testing days and from
consuming psychoactive substances or other medications for 2 weeks before testing days
and for the duration of the study

- Able and willing to comply with all study requirements

- Informed consent form was signed

- Good knowledge of the German language

Exclusion Criteria:

- Previous significant adverse response to a hallucinogenic drug

- Participation in another study where pharmaceutical compounds will be given

- Self or first-degree relatives with present or antecedent psychiatric disorders

- History of head trauma or fainting

- Recent cardiac or brain surgery

- Current use of medication or psychotropic substances (including nicotine addiction)

- Presence of major internal or neurological disorders (including sepsis,
pheochromocytoma, thyrotoxicosis, drug-induced fibrosis, familiar or basilar artery
migraine)

- Cardiovascular disease (hypertonia, coronary artery disease, heart insufficiency,
myocardial infarction, coronary spastic angina)

- Peripheral vascular disease (thromboangiitis obliterans, luetic arteritis, severe
arteriosclerosis, thrombophlebitis, Raynaud's disease)

- Liver or renal disease